You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 66 No. 6, June 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •eTables
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Psychiatry
 •Psychopharmacology
 •Schizophrenia
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors

A Positron Emission Tomography Study With [11C]-(+)-PHNO

Ariel Graff-Guerrero, MD, PhD; David Mamo, MD, MSc; C. M. Shammi, MD; Romina Mizrahi, MD, PhD; Heidi Marcon, BSc; Penny Barsoum, RN; Pablo Rusjan, PhD; Sylvain Houle, MD, PhD; Alan A. Wilson, PhD; Shitij Kapur, MD, PhD

Arch Gen Psychiatry. 2009;66(6):606-615.

Context  Most antipsychotics are thought to have an effect on D2 and D3 receptors. The development of carbon 11–labeled (+)-4-propyl-9-hydroxynaphthoxazine ([11C]-(+)-PHNO), the first agonist radioligand with higher affinity for D3 than D2 receptors, allows one to differentiate the effects of antipsychotics on high-affinity vs low-affinity sites of the D2 receptor and on D3 vs D2 receptor subtypes.

Objectives  To examine the effects of antipsychotics (clozapine, risperidone, or olanzapine) on the high- vs high- + low-affinity sites of the D2 and D3 receptors by comparing the [11C]-(+)-PHNO and [11C]raclopride binding in the D3 receptor–rich (globus pallidus and ventral striatum) and D2 receptor–rich (caudate and putamen) regions.

Design  Two sequential studies with different participants and appropriate controls were performed. The first compared the occupancy produced by 3 antipsychotics as measured with [11C]-(+)-PHNO and [11C]raclopride. The second was a double-blind, placebo-controlled experiment to compare the effect of pramipexole (a D3 receptor–preferring agonist) vs placebo on the increased [11C]-(+)-PHNO signal observed in the globus pallidus of patients.

Setting  Positron Emission Tomography Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.

Participants  Twenty-three patients with schizophrenia and 23 healthy controls.

Main Outcome Measures  Antipsychotic occupancies as measured with [11C]-(+)-PHNO and [11C]raclopride.

Results  The antipsychotic-treated patients showed high occupancies with both [11C]-(+)-PHNO and [11C]raclopride in the dorsal striatum, with [11C]raclopride occupancies about 20% higher. Most strikingly, patients did not show any occupancy with [11C]-(+)-PHNO in the globus pallidus as compared with normal controls or with their own scans using [11C]raclopride. This unblocked [11C]-(+)-PHNO signal was displaced by a single dose of pramipexole.

Conclusions  Antipsychotics block both the high- and low-affinity states of the D2 receptors across the brain, but antipsychotic treatment does not block the [11C]-(+)-PHNO signal in the D3 receptor–rich regions, despite the ongoing D2 receptor blockade. This [11C]-(+)-PHNO signal in regions such as the globus pallidus seems increased despite antipsychotic treatment and is displaceable by a D3 receptor–preferring agonist. The radiotracer [11C]-(+)-PHNO and the data open up new avenues for exploring the potential therapeutic significance of the D3 receptor in schizophrenia.


Author Affiliations: Positron Emission Tomography Centre, Centre for Addiction and Mental Health (Drs Graff-Guerrero, Mamo, Shammi, Mizrahi, Rusjan, Houle, Wilson, and Kapur and Mss Marcon and Barsoum) and Department of Psychiatry, University of Toronto (Drs Graff-Guerrero, Mamo, Shammi, Mizrahi, Houle, Wilson, and Kapur), Toronto, Ontario, Canada; Institute of Neurobiology, Universidad Naciónal Autonoma de México, Mexico City (Dr Graff-Guerrero); and Division of Psychological Medicine and Psychiatry, Institute of Psychiatry, King's College London, London, England (Dr Kapur).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

This Month in Archives of General Psychiatry
Arch Gen Psychiatry. 2009;66(6):579.
FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.